title: The additive effect of p53 Arg72Pro and RNASEL Arg462Gln genotypes on age of disease onset in Lynch syndrome patients with pathogenic germline mutations in MSH2 or MLH1.
abstract: p53 and the prostate-cancer-susceptibility gene RNASEL are tumour suppressor genes involved in apoptosis. We have previously reported that the common, functionally different variants Arg72Pro in p53 and Arg462Gln in RNASEL are associated with the age of disease onset of colorectal cancer in Lynch syndrome patients. To assess the combined effect of both variants, we screened 246 unrelated Lynch syndrome patients with a pathogenic germline mutation either in MSH2 (n=138) or in MLH1 (n=108) and colorectal cancer as first tumour, and 245 healthy controls. The global log rank test revealed significant differences in the age of disease onset for the genotypes of each variant (p=0.0176 for p53 and p=0.0358 for RNASEL) and for the combined genotypes of both variants (p=0.0174). The highest difference in median age of disease onset was seen between homozygotes for the wild-types in both genes (42years [range 22-75]) and homozygotes for the variant alleles in both genes (30years [range 26-47]). A multivariate Cox regression model indicated that only the p53 and RNASEL genotypes had a significant influence on age of disease onset (p=0.016 for p53 and p=0.014 for RNASEL) in an additive mode of inheritance, and that the effects of both variants are purely additive, which supports the notion that the p53 and RNaseL pathways do not interact. These findings may be relevant for preventive strategies in Lynch syndrome.
authors.affiliation: Department of Surgical Research, Dresden University of Technology, D-01307 Dresden, Germany. Stefan.Krueger@tu-dresden.de
authors.forename: Stefan
authors.initials: S
authors.lastname: Krüger
authors.forename: Christoph
authors.initials: C
authors.lastname: Engel
authors.forename: Andrea
authors.initials: A
authors.lastname: Bier
authors.forename: Ann-Sophie
authors.initials: AS
authors.lastname: Silber
authors.forename: Heike
authors.initials: H
authors.lastname: Görgens
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Mangold
authors.forename: Constanze
authors.initials: C
authors.lastname: Pagenstecher
authors.forename: Elke
authors.initials: E
authors.lastname: Holinski-Feder
authors.forename: Magnus
authors.initials: M
authors.lastname: von Knebel Doeberitz
authors.forename: Brigitte
authors.initials: B
authors.lastname: Royer-Pokora
authors.forename: Stefan
authors.initials: S
authors.lastname: Dechant
authors.forename: Christian
authors.initials: C
authors.lastname: Pox
authors.forename: Nils
authors.initials: N
authors.lastname: Rahner
authors.forename: Annegret
authors.initials: A
authors.lastname: Müller
authors.forename: Hans K
authors.initials: HK
authors.lastname: Schackert
mesh_terms: D048868:Adaptor Proteins, Signal Transducing / Q000235:genetics*; D000328:Adult; D017668:Age of Onset; D000368:Aged; D019943:Amino Acid Substitution; D001120:Arginine / Q000737:chemistry / Q000235:genetics; D003123:Colorectal Neoplasms, Hereditary Nonpolyposis / Q000453:epidemiology* / Q000235:genetics; D004722:Endoribonucleases / Q000235:genetics*; D005260:Female; D005838:Genotype; D018095:Germ-Line Mutation; D006801:Humans; D008297:Male; D008875:Middle Aged; D000070957:MutL Protein Homolog 1; D051718:MutS Homolog 2 Protein / Q000235:genetics*; D009687:Nuclear Proteins / Q000235:genetics*; D011392:Proline / Q000737:chemistry / Q000235:genetics; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
chemical_list: D048868:Adaptor Proteins, Signal Transducing; C501486:MLH1 protein, human; D009687:Nuclear Proteins; D016159:Tumor Suppressor Protein p53; D001120:Arginine; D011392:Proline; D004722:Endoribonucleases; C031956:2-5A-dependent ribonuclease; C497172:MSH2 protein, human; D000070957:MutL Protein Homolog 1; D051718:MutS Homolog 2 Protein